Aeglea Bio Therapeutics Stock Price. Everything You Need To Know About The Aeglea Bio Therapeutics Stock!
Aeglea Biotherapeutics, Inc. is a biotechnology company that’s committed to developing groundbreaking solutions for rare and high-burden diseases. Based in Austin, Texas, the company employs a team of 69 full-time professionals and went public in 2016. Aeglea is dedicated to the development of human enzyme therapeutics, which can address rare metabolic diseases and improve patient outcomes.
One of Aeglea’s most promising product candidates is Pegtarviliase, which is a novel human enzyme designed to reduce elevated levels of total homocysteine in the plasma. Pegtarviliase is PEGylated, which means it’s modified with polyethylene glycol to enhance its therapeutic properties. This innovative enzyme has been engineered using directed mutagenesis of amino acids within the wild-type human cystathionine y-lyase enzyme (CGL).
Aeglea’s second product candidate, Pegzilarginase, is another PEGylated human enzyme that’s designed to enzymatically degrade the amino acid arginine. Pegzilarginase is being developed to lower arginine levels in patients with Arginase 1 Deficiency. The company has enhanced the stability and arginine-degrading activity of the enzyme in human plasma by engineering Pegzilarginase with modifications.
Currently, Aeglea is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE trial and Phase I/II open-label extension trial. It’s important to stay up-to-date with the latest developments in the industry and keep track of how Aeglea’s stocks share price today and premarket are performing. By conducting thorough research, investors can make informed decisions about whether Aeglea Biotherapeutics is a company that aligns with their investment objectives.
Aeglea Bio Therapeutics Stock Price. Everything You Need To Know About The Aeglea Bio Therapeutics Stock! performance
- Employees 69
- Company HQ Austin
- Website https://www.aeglea.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
Are you a retail investor from Malaysia, Thailand, Indonesia or Vietnam looking to diversify your investment portfolio? Look no further than Aeglea Bio Therapeutics, a promising bio-pharmaceutical company. Investing in Aeglea Bio Therapeutics can offer significant growth potential, especially as the demand for innovative biotech solutions continues to rise. But how can retail investors from Malaysia, Thailand, Indonesia, and Vietnam invest in this stock? Zorion, the leading investment platform, offers a seamless and user-friendly interface for investors to invest in real US stocks and Pre-IPO companies like Aeglea Bio Therapeutics. With Zorion’s investment insights and recommendations, paired with access to educational materials, you can confidently make informed decisions about your investment journey. Start investing in Aeglea Bio Therapeutics today and pave the way for a brighter financial future.
